GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
Frequently asked questions
What sector does GeneDx Holdings Corp. (WGS) operate in?
GeneDx Holdings Corp. belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is GeneDx Holdings Corp. (WGS) current stock price?
As of the latest data, GeneDx Holdings Corp. stock price is $61.26, with a previous close of $56.15. GeneDx Holdings Corp. gained $5.11 in the last trading session, representing a 9.1% increase.
What is GeneDx Holdings Corp. (WGS) current market capitalization?
GeneDx Holdings Corp. market cap is approximately 1.83 billion.
What is GeneDx Holdings Corp. (WGS) Earnings Per Share (EPS)?
The trailing EPS is -$3.63, and the forward EPS is $1.20.
What is GeneDx Holdings Corp. (WGS) EBITDA?
GeneDx Holdings Corp. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -10.36 million.
Does GeneDx Holdings Corp. (WGS) pay dividends?
No. GeneDx Holdings Corp. does not pay a dividend.
How did GeneDx Holdings Corp. (WGS) perform in its most recent earnings report?
In the last report (June 30, 2026), GeneDx Holdings Corp. posted an EPS surprise of 105.26% and a revenue surprise of 3.09%.
When is GeneDx Holdings Corp. (WGS) next earnings report?
GeneDx Holdings Corp. is expected to release its next earnings report on September 30, 2026.
What is GeneDx Holdings Corp. (WGS) beta (volatility) score?
GeneDx Holdings Corp. has a beta of 2.007, indicating very high volatility compared to the market.
